血管紧张素受体拮抗剂伊贝沙坦治疗高血压的疗效及依从性  

Therapeutic effects of angiotensin receptor blocker irbesartan on hypertension and its compliance

作　　者：谷永江 GU Yong-jiang(Department of Internal Medicine, Traditional Chinese Medicine Hospital of Changping District, Beijing, 102200, China)

机构地区：[1]北京市昌平区中医医院内科,北京市102200

出　　处：《心血管康复医学杂志》2017年第3期292-295,共4页Chinese Journal of Cardiovascular Rehabilitation Medicine

摘　　要：目的:探讨血管紧张素受体拮抗剂(伊贝沙坦)治疗高血压的疗效及依从性。方法:选择在我院接受治疗的200例高血压患者为研究对象,均分为阿替洛尔组与伊贝沙坦组,比较两组疗效,治疗后血压、血脂水平以及血流动力学指标的变化。结果:治疗后,伊贝沙坦组总有效率明显高于阿替洛尔组(98.0%比72.0%,P=0.001)。与阿替洛尔组比较,伊贝沙坦组收缩压[(131.5±8.4)mmHg比(122.2±7.5)mmHg],舒张压[(122.2±7.5)mmHg比(83.6±4.4)mmHg],甘油三酯[(7.5±1.5)mmol/L比(5.2±1.2)mmol/L]水平、全血高切黏度[(6.7±0.7)mPa·s比(6.1±0.4)mPa·s]、全血低切黏度[(10.5±0.7)mPa·s比(9.2±0.6)mPa·s]、血浆高切黏度[(1.9±0.2)mPa·s比(1.5±0.1)mPa·s]均明显降低(P均<0.01)。伊贝沙坦组患者治疗依从性明显高于阿替洛尔组(95.0%比63.0%,P=0.001)。结论:高血压患者采用血管紧张素受体拮抗剂伊贝沙坦治疗效果显著,安全可靠,依从性较高,值得推广。Objective： To explore therapeutic effects of angiotensin receptor blocker （irbesartan） on hypertension and its compliance. Methods： A total of 200 cases with hypertension treated in our hospital were selected, randomly and equally divided into atenolol group and irbesartan group. Therapeutic effect, levels of blood pressure and blood lipids, and hemodynamic indexes were compared between two groups after treatment. Results： After treatment, total effective rate of irbesartan group was significantly higher than that of atenolol group （98.0% vs. 72.0%, P = 0.001）. Compared with atenolol group, there were significant reductions in systolic blood pressure [ （131.5 -± 8. 4） mmHg vs. （122.2±7.5） mmHg], diastolic blood pressure [ （122.2±7.5） mmHg vs. （83.6±4.4） mmHg], blood triglyceride level [ （7.5 ± 1.5） mmol/L vs. （5.2 ± 1.2） mmol/L], whole blood high shear viscosity [ （6, 7 ± 0.7） mPa.svs. （6.1-±0.4） mPa. s], whole blood low shear viscosity[ （10.5±0.7） mPasvs. （9.2±0.6） mPa s] and plasma high shear viscosity [ （1.9 ± 0.2） mPa s vs. （1.5 ± 0.1） mPa s] in irbesartan group, P〈0.01 all. Therapeutic compliance of irbesartan group was significantly higher than that of atenolol group （95.0% vs. 63.0%, P = 0. 001）. Conclusion： Angiotensin receptor blockers irbesartan possess significant therapeutic effect on patients with hypertension. It is safe and reliable with high compliance, which is worth extending.

关 键 词：高血压 血管紧张素受体拮抗剂 服药依从性 疗效 

分 类 号：R544.1[医药卫生—心血管疾病]